Trial Profile
A first in human study of chimeric antigen receptor T-cell therapy
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2018
Price :
$35
*
At a glance
- Drugs CAR-T cell therapies (Primary)
- Indications Cancer; Multiple myeloma; Solid tumours
- Focus Adverse reactions; First in man
- 16 Sep 2018 New trial record
- 04 Sep 2018 According to a Helix BioPharma media release, the company plans to initiate this study in 2019.